74 results on '"Anti-HIV Agents economics"'
Search Results
2. Prevention. Using early ART to prevent transmission is cost effective.
3. Prevention. Using PrEP cost-effective in high-risk MSM groups.
4. Guidance. Guideline implementation would reduce transmission, costs.
5. Treatment. HIV drug spending up; Merck offers discounts.
6. Treatment. Antiretroviral adherence results in lower health care costs, study says.
7. Policy. Group says health reform must address HIV treatment.
8. Drug pricing. AHF praises U.S. drugmaker for AIDS drug price freeze.
9. Financial. Dismissal reversed for discharge of HIV-positive student's loans.
10. Insurance. Survey: Medicare drug plan fails HIV patients.
11. PEPFAR claims gains in global fight against AIDS.
12. California: ADAP problems require national solution.
13. ADAP waiting lists persist, additional resources needed.
14. Dismissal upheld in HIV drug monopoly claim.
15. Drug pricing. AHF cautions company over new AIDS drug price.
16. CARE Act. Action urged to preserve housing, AIDS drug funding.
17. Funding. Senate committee passes CARE Act reauthorization bill.
18. Advocates praise Schwarzenegger for fully funding ADAP.
19. Inflation. Price hikes on AIDS drug not protected by antitrust laws.
20. National foundation: AIDS drug prices still too high for poor.
21. CMS: Medicare drug formularies to cover most HIV drugs.
22. AIDS activists decry steady hikes in HIV drug prices.
23. Cost imposes barrier to HIV treatment in Missouri.
24. Medicaid prescription limit could hurt HIV patients.
25. Bankruptcy. Money used for HIV drugs leaves nondischargeable debt.
26. ADAP. Report: Alabama has longest wait list for AIDS drugs.
27. New Medicare guidelines fail to protect those with HIV/AIDS.
28. Drug pricing. Drug companies close booths at conference amid activist pressure.
29. Some states hopeful over federal assistance for ADAPs.
30. Feds give ADAPs boost to eliminate waiting lists.
31. ADAP. Rationing of AIDS drugs feared.
32. States implement emergency measures to keep ADAPs alive.
33. One-third of people on ADAP waiting list from Colorado.
34. Clinton-brokered AIDS drug-price agreement to benefit millions.
35. Drug access. Coalition calls for drugmakers to lower AIDS drug prices.
36. CalPERS to reopen drug giant's AIDS drug-pricing issue.
37. Drug pricing. AHF to file suit against Glaxo for African AIDS-related deaths.
38. Africa finds drug giants guilty of excessive pricing.
39. Fraud. Conviction upheld in bogus HIV drug investment scheme.
40. AIDS director: ADAP a crisis in West Virginia.
41. List of states with ADAP restrictions continues to grow.
42. Calif. AIDS groups reject ADAP co-pay.
43. ADAP. Group presses for price concessions on AIDS drugs.
44. Drug assistance. ADAP seeks emergency funds.
45. Firms fumble for grip on HIV.
46. Glaxo drops drug prices, AIDS foundation drops suit.
47. Anatomy of a successful campaign to lower AIDS drug prices.
48. HHS awards $1 billion in Ryan White grants.
49. States unite to press for price concessions on AIDS drugs.
50. Drug cost. States concerned about Fuzeon.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.